MORRISVILLE, N.C., May 30, 2013 (GLOBE NEWSWIRE) -- Arrhythmia and Electrophysiology Review has published single-center outcomes using the Convergent Procedure, an epicardial-endocardial ablation approach to treat patients with symptomatic, persistent atrial fibrillation (AF). AF is the most common cardiac arrhythmia, estimated to affect 5.9 million people in the U.S., with a majority of these patients falling into the persistent AF population.
The Physicians at Allegheny General Hospital in Pittsburgh, PA, evaluated 42 patients, 86% of whom had persistent AF. Persistent AF is often characterized by debilitating patient symptoms as well as the presence of structural heart disease and enlarged atria, both of which may be correlated with repeat procedures and complications in standalone endocardial ablation. In this study, 66% of patients had enlarged atria greater than 130 ml in volume.
The publication reported 79% (31 of 39) of patients in sinus rhythm at 3 months, 89% (24 of 27) at 6 months, and 9 of 9 who had reached 12 month follow-up. No major adverse events were observed.
"The Convergent Procedure utilizes a combined epicardial-endocardial approach and has provided us with a more comprehensive option for difficult-to-treat atrial fibrillation," said Amit J. Thosani, MD, of the Center for Atrial Fibrillation at Allegheny General Hospital, Pittsburgh, PA. "These outcomes are promising for persistent and longstanding persistent AF patients, including those with enlarged atria."
The multidisciplinary Convergent Procedure is performed as a single procedure in the electrophysiology lab. The epicardial component of the procedure is completed with no chest incisions or ports, using the proprietary transdiaphragmatic approach that requires a 2 cm incision in the abdomen, providing the surgeon with direct visualization to create lesions across the atrium.
This publication can be found in the current issue of Arrhythmia and Electrophysiology Review at http://www.touchcardiology.com/journals/editions/arrhythmia-electrophysiology-review-volume-2-issue-1
About nContact, Inc.
nContact, Inc. is a leading innovator in epicardial ablation devices and techniques. Its mission is to transform the underserved arrhythmia market through the advancement of less invasive, more efficacious ablation alternatives for cardiac arrhythmias. The Company's lead technologies, EPi-Sense® and Numeris® Coagulation Systems with VisiTrax,® have CE Mark approval in Europe for the coagulation of cardiac tissue in the treatment of atrial fibrillation and atrial flutter. The EPi-Sense and Numeris Coagulation Systems with VisiTrax are indicated for endoscopic coagulation of cardiac tissue in the U.S. nContact was founded in 2005 and is headquartered in Morrisville, North Carolina, USA.